Style | Citing Format |
---|---|
MLA | Bafrani MA, et al.. "The Coincidence of Multiple Sclerosis and Primary Vasculitis; From the Bench of Pathology to the Bedside of Treatment: A Systematic Review of Case Reports." Neurological Sciences, vol. 46, no. 1, 2025, pp. 351-364. |
APA | Bafrani MA, Asadigandomani H, Kasbi NA, Heidari H, Eskandarieh S (2025). The Coincidence of Multiple Sclerosis and Primary Vasculitis; From the Bench of Pathology to the Bedside of Treatment: A Systematic Review of Case Reports. Neurological Sciences, 46(1), 351-364. |
Chicago | Bafrani MA, Asadigandomani H, Kasbi NA, Heidari H, Eskandarieh S. "The Coincidence of Multiple Sclerosis and Primary Vasculitis; From the Bench of Pathology to the Bedside of Treatment: A Systematic Review of Case Reports." Neurological Sciences 46, no. 1 (2025): 351-364. |
Harvard | Bafrani MA et al. (2025) 'The Coincidence of Multiple Sclerosis and Primary Vasculitis; From the Bench of Pathology to the Bedside of Treatment: A Systematic Review of Case Reports', Neurological Sciences, 46(1), pp. 351-364. |
Vancouver | Bafrani MA, Asadigandomani H, Kasbi NA, Heidari H, Eskandarieh S. The Coincidence of Multiple Sclerosis and Primary Vasculitis; From the Bench of Pathology to the Bedside of Treatment: A Systematic Review of Case Reports. Neurological Sciences. 2025;46(1):351-364. |
BibTex | @article{ author = {Bafrani MA and Asadigandomani H and Kasbi NA and Heidari H and Eskandarieh S}, title = {The Coincidence of Multiple Sclerosis and Primary Vasculitis; From the Bench of Pathology to the Bedside of Treatment: A Systematic Review of Case Reports}, journal = {Neurological Sciences}, volume = {46}, number = {1}, pages = {351-364}, year = {2025} } |
RIS | TY - JOUR AU - Bafrani MA AU - Asadigandomani H AU - Kasbi NA AU - Heidari H AU - Eskandarieh S TI - The Coincidence of Multiple Sclerosis and Primary Vasculitis; From the Bench of Pathology to the Bedside of Treatment: A Systematic Review of Case Reports JO - Neurological Sciences VL - 46 IS - 1 SP - 351 EP - 364 PY - 2025 ER - |